The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study;Virkningen af losartan versus atenolol på kardiovaskulær morbiditet og mortalitet hos patienter med diabetes mellitus i LIFE-undersøgelsen

Ugeskrift for Laeger

Volumn 165, Issue 5, 2003, Pages 459-462

  Ibsen, Hans ^a   Lindholm, Lars H ^b   Pedersen, Ole Lederballe ^b   Dahlöf, Björn ^b   Kjeldsen, Sverre E ^b  

^a Medicinsk Afdeling M   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; LOSARTAN; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; ELECTROCARDIOGRAM; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; RANDOMIZED CONTROLLED TRIAL; STROKE;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANTIHYPERTENSIVE AGENTS; ATENOLOL; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; RISK FACTORS;

EID: 0037467982     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
2. Lindholm LH, Ibsen H, Dahlöf B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-10.
3. Ibsen H, Pedersen OL, Dahlöf B et al. Virkningen af losartan versus atenolol på kardiovaskulær morbiditet og mortalitet hos patienter med hypertension og ekg-verificeret venstre ventrikelhypertrofi i LIFE -under-søgelsen. Ugeskr Læger 2003; 165(i trykken).
4. Stamler J, Vaccaro O, Neaton JD et al. Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-44.
5. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-21.
6. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
7. Guidelines Sub-Committee. 1999 World Health Organisation-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151-83.
8. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-6.
9. Devereux RB, Roman MJ, Paranicas M et al. Impact of diabetes on cardiac structure and function: the Strong Heart Study. Circulation 2000; 101: 2271-6.
10. Palmied V, Bella JN, Arnett DK et al. Effect of type II diabetes on left ventricular geometry and function: the Hypertension Genetic Epidemiology Network (HyperGEN) Study. Circulation 2001; 103: 102-7.
11. Bella JN, Devereux RB, Roman MJ et al. Separate and joint effects of hypertension and diabetes mellitus on left ventricular structure and function: the Strong Heart Study. Am J Cardiol 2001; 87: 1260-5.
12. Brenner BM, Cooper ME, de Zeeuw D et at al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
13. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients, with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.